Literature DB >> 21218532

Gamma Knife surgery in patients harboring orbital cavernous hemangiomas that were diagnosed on the basis of imaging findings.

Xiaomin Liu1, Desheng Xu, Yipei Zhang, Dong Liu, Guoxiang Song.   

Abstract

OBJECT: This study was undertaken to evaluate clinical outcomes and tumor control in patients harboring orbital cavernous hemangiomas (OCHs) that had been diagnosed based on findings of imaging studies and treated by Gamma Knife surgery (GKS).
METHODS: Between 1995 and 2008, 23 patients harboring OCHs that had been diagnosed on the basis of imaging findings were treated using GKS; complete follow-up data are available in all cases. The median treatment volume was 1.5 cm³ (range 0.15-10.10 cm³), the median tumor margin dose was 15 Gy (range 12-20 Gy), and the median follow-up period was 12 months (range 6-120 months).
RESULTS: A decrease in tumor size was found in 20 patients, and no tumor progression was observed after GKS. Eleven of 14 patients whose visual function had been adversely affected prior to treatment had improved visual acuity at the last assessment. Side effects of the procedure included orbital pain in 3 patients and chemosis in 2 patients.
CONCLUSIONS: In this preliminary experience, GKS proved to be an effective treatment for OCHs diagnosed on the basis of imaging findings. Additional follow-up is necessary, and the long-term side effects of the procedure still need to be determined.

Entities:  

Mesh:

Year:  2010        PMID: 21218532

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  2 in total

1.  Stereotactic gamma knife radiosurgery for orbital cavernous hemangioma: clinical outcome and visual function protection.

Authors:  Hsien-Chung Chen; Chaur-Jong Hu; David Hung-Chi Pan
Journal:  J Neurooncol       Date:  2021-01-24       Impact factor: 4.130

2.  Stereotactic radiosurgery for orbital cavernous venous malformation: a single center's experience for 15 years.

Authors:  Won Jae Lee; Kyung-Rae Cho; Jung-Won Choi; Doo-Sik Kong; Ho Jun Seol; Do-Hyun Nam; Yoon-Duck Kim; Kyung In Woo; Jung-Il Lee
Journal:  Acta Neurochir (Wien)       Date:  2020-09-15       Impact factor: 2.216

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.